dc.contributor
Institut Català de la Salut
dc.contributor
[Raposeiras-Roubín S, Jamhour K, Abu-Assi E] Cardiology Department, Hospital Universitario Álvaro Cunqueiro, Vigo, Spain. [Núñez-Gil IJ, Vedia O] Cardiology Department, Hospital Clínico San Carlos, Madrid, Spain. [Conty DA] Cardiology Department, Hospital de Navarra, Pamplona, Spain. [Andrés M] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Jamhour, Karim
dc.contributor.author
Abu-Assi, Emad
dc.contributor.author
Conty, David Aritza
dc.contributor.author
Vedia Cruz, Oscar
dc.contributor.author
RAPOSEIRAS-ROUBIN, SERGIO
dc.contributor.author
Nuñez Gil, Ivan Javier
dc.contributor.author
Andrés Villarreal, Mireia
dc.date.accessioned
2025-10-24T10:42:34Z
dc.date.available
2025-10-24T10:42:34Z
dc.date.issued
2023-09-01T07:31:18Z
dc.date.issued
2023-09-01T07:31:18Z
dc.identifier
Raposeiras-Roubín S, Núñez-Gil IJ, Jamhour K, Abu-Assi E, Conty DA, Vedia O, et al. Long-term prognostic impact of beta-blockers in patients with Takotsubo syndrome: Results from the RETAKO Registry. Rev Port Cardiol. 2023 Mar;42(3):237–46.
dc.identifier
https://hdl.handle.net/11351/10203
dc.identifier
10.1016/j.repc.2022.02.010
dc.identifier
000950235400001
dc.identifier.uri
https://hdl.handle.net/11351/10203
dc.description.abstract
Beta-blocker; Mortality; Takotsubo
dc.description.abstract
Bloqueador beta; Mortalidad; Takotsubo
dc.description.abstract
Bloquejador beta; Mortalitat; Takotsubo
dc.description.abstract
Background
No evidence-based therapy has yet been established for Takotsubo syndrome (TTS). Given the putative harmful effects of catecholamines in patients with TTS, beta-blockers may potentially decrease the intensity of the detrimental cardiac effects in those patients.
Objective
The purpose of this study was to assess the impact of beta-blocker therapy on long-term mortality and TTS recurrence.
Methods
The cohort study used the national Spanish Registry on TakoTsubo Syndrome (RETAKO). A total of 970 TTS post-discharge survivors, without pheochromocytoma, left ventricular outflow tract obstruction, sustained ventricular arrhythmias, and significant bradyarrhythmias, between January 1, 2003, and July 31, 2018, were assessed. Cox regression analysis and inverse probability weighting (IPW) propensity score analysis were used to evaluate the association between beta-blocker therapy and survival free of TTS recurrence.
Results
From 970 TTS patients, 582 (60.0%) received beta-blockers. During a mean follow-up of 2.5 ± 3.3 years, there were 87 deaths (3.6 per 100 patients/year) and 29 TTS recurrences (1.2 per 100 patient/year). There was no significant difference in follow-up mortality or TTS recurrence in unadjusted and adjusted Cox analysis (hazard ratio [HR] 0.86, 95% confidence interval [CI] 0.59–1.27, and 0.95, 95% CI 0.57–1.13, respectively). After weighting and adjusting by IPW, differences in one-year survival free of TTS recurrence between patients treated and untreated with beta-blockers were not found (average treatment effect −0.01, 95% CI −0.07 to 0.04; p=0.621).
Conclusions
In this observational nationwide study from Spain, there was no significant association between beta-blocker therapy and follow-up survival free of TTS recurrence.
dc.description.abstract
The Retako webpage was funded by a non-conditional Astrazeneca scholarship.
dc.format
application/pdf
dc.format
application/pdf
dc.relation
Revista Portuguesa de Cardiologia;42(3)
dc.relation
https://doi.org/10.1016/j.repc.2022.02.010
dc.rights
Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Miocardi - Malalties - Prognosi
dc.subject
Miocardi - Malalties - Tractament
dc.subject
Beta-blocadors - Ús terapèutic
dc.subject
DISEASES::Cardiovascular Diseases::Heart Diseases::Ventricular Dysfunction::Ventricular Dysfunction, Left::Takotsubo Cardiomyopathy
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Neurotransmitter Agents::Adrenergic Agents::Adrenergic Antagonists::Adrenergic beta-Antagonists
dc.subject
Other subheadings::Other subheadings::/therapeutic use
dc.subject
ENFERMEDADES::enfermedades cardiovasculares::enfermedades cardíacas::disfunción ventricular::disfunción ventricular izquierda::miocardiopatía de Takotsubo
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::neurotransmisores::adrenérgicos::antagonistas adrenérgicos::antagonistas adrenérgicos beta
dc.subject
Otros calificadores::Otros calificadores::/uso terapéutico
dc.title
Long-term prognostic impact of beta-blockers in patients with Takotsubo syndrome: Results from the RETAKO Registry
dc.title
Impacto prognóstico a longo prazo do uso de beta-bloqueantes em doentes com síndrome de Takotsubo: resultados do Registo RETAKO
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
